<DOC>
	<DOCNO>NCT02445872</DOCNO>
	<brief_summary>Aprepitant oral neurokinin-1 ( NK-1 ) antagonist use prevention chemotherapy-induced nausea vomiting ( CINV ) . This phase II clinical trial design evaluate efficacy aprepitant prevention CINV lung cancer patient receive 3-day cisplatin-based chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy Aprepitant CINV Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy</brief_title>
	<detailed_description>Patients pathologic diagnose advanced non-small cell lung cancer , accord NCCN non-small cell lung cancer guide line ( 2015 V1 ) .The patient receive 3-day cisplatin-based chemotherapy , randomize divide two group , aprepitant group placebo group . In aprepitant group , patient would receive aprepitant ( 125 mg po day1 , 80 mg day2-3 ) combination palonosetron dexamethasone ( 5mg iv day1-3 , 3.75mg po day4-5 ) . In placebo group patient would receive palonosetron dexamethasone ( 5mg iv day1-3 , 7.5mg po day4-5 ) .During treatment , grade nausea vomit record order evaluate complete response rate CINV , side-effects record .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>1 . Patient confirm lung cancer pathologic histology cytology . 2 . Males female age ≥18 year , &lt; 80 year . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Life expectancy ≥12 week . 4 . Males female contraceptive period trial 8 week last administration drug . 5 . Patients asymptomatic , treat brain metastasis eligible trial participation . 6 . Adequate bone marrow , renal , liver function require . 7 . Able comply require protocol followup procedure , able receive oral medication . 8 . Institutional review boardapproved informed consent obtain every patient initiation trialspecific procedure treatment . 1 . History sensitivity/idiosyncrasy aprepitant excipients 2 . Condition might interfere drug absorption , distribution metabolism excretion . 3 . Concomitant use agent know interfere aprepitant pharmacokinetics 4 . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . 5 . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication , active peptic ulcer disease . 6 . Female subject pregnant breastfeeding . 7 . Inadequate hematological function . 8 . Abnormal liver renal function . 9 . Patient assess investigator unable unwilling comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Chemotherapy-induced Nausea Vomiting</keyword>
	<keyword>CINV</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Lung cancer</keyword>
</DOC>